Previous Close | 20.28 |
Open | 32.29 |
Bid | 34.72 x 1000 |
Ask | 35.04 x 800 |
Day's Range | 32.13 - 37.26 |
52 Week Range | 4.49 - 37.26 |
Volume | |
Avg. Volume | 1,088,757 |
Market Cap | 4.556B |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.85 |
Earnings Date | Nov 02, 2023 - Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.92 |
Subscribe to Yahoo Finance Plus to view Fair Value for IMVT
For instance, Monday's trading session gave market participants some optimism about how the economy could weather difficult times, but based on Tuesday morning's stock index futures movements, it's just difficult to build lasting positive momentum. Based on current futures levels, stocks looked poised to give back much of Monday's gains at the open on Tuesday morning. Both Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV) are relatively small players in biotech right now, but the latest news on one candidate treatment had investors feeling better about their long-term prospects.
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. To participate in the conference call, please register in advance here. To access the live a